These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 17948847)
1. Preventing RSV in pediatric patients: improving the outcome at home. Borell M; Myers J; Rineair S Caring; 2007 Sep; 26(9):34-7. PubMed ID: 17948847 [No Abstract] [Full Text] [Related]
2. Health plan pharmacy director: considerations for treatment and management of RSV disease. Burgoyne DS Manag Care; 2008 Nov; 17(11 Suppl 12):17-8, discussion 18-9. PubMed ID: 19102025 [TBL] [Abstract][Full Text] [Related]
3. Give Synagis via home health. Goldenring J Pediatrics; 2007 Jan; 119(1):219. PubMed ID: 17200293 [No Abstract] [Full Text] [Related]
4. In the trenches: a pediatrician's perspective on prevention and treatment strategies for RSV disease. Frogel MP Manag Care; 2008 Nov; 17(11 Suppl 12):7-12, discussion 18-9. PubMed ID: 19097557 [TBL] [Abstract][Full Text] [Related]
5. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J; Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822 [TBL] [Abstract][Full Text] [Related]
6. Give Synagis via home care: a reply. Schipper JA Pediatrics; 2007 Jun; 119(6):1258-9; author reply 1259. PubMed ID: 17545406 [No Abstract] [Full Text] [Related]
11. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443 [TBL] [Abstract][Full Text] [Related]
12. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis. Afghani B; Ngo T; Leu SY; Wu FL; Cecilio M; Aron-Johnson P; Zeitany R; Sills J; Amin A Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124 [TBL] [Abstract][Full Text] [Related]
13. A health care management company's experience with palivizumab. Silverman W Manag Care; 2002 Jan; 11(1):45-6. PubMed ID: 11828875 [No Abstract] [Full Text] [Related]
14. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632 [No Abstract] [Full Text] [Related]
15. A health care management company's experience with palivizumab--1 year later. Silverman W Manag Care; 2003 May; 12(5):49-50. PubMed ID: 12800748 [No Abstract] [Full Text] [Related]
16. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Fitzgerald DA Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385 [TBL] [Abstract][Full Text] [Related]
17. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units. Kurz H; Herbich K; Janata O; Sterniste W; Bauer K J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241 [TBL] [Abstract][Full Text] [Related]
18. Managed care considerations: vulnerable populations and prevention strategies for respiratory syncytial virus disease. Peskin SR Manag Care; 2008 Nov; 17(11 Suppl 12):preceding table of contents. PubMed ID: 19097555 [No Abstract] [Full Text] [Related]
19. Health plan medical director: considerations for prevention and management of RSV disease. Tzeel A Manag Care; 2008 Nov; 17(11 Suppl 12):15-7, discussion 18-9. PubMed ID: 19097559 [TBL] [Abstract][Full Text] [Related]